Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized dose-ranging study of AZD5462 in chronic heart failure
NL-OMON59400Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing AZD5462 with Placebo (2 arms). Primary endpoint: Change in echocardiographic measurements from Baseline to Week 25. Started Jul 2024; status: completed.
02
Drugs
AZD5462
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON59400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59400.